CDMOs at a Crossroads: Scaling, Adapting, and Partnering for the Future

The CDMO industry is at an inflection point. The explosive demand for GLP-1 therapies is straining manufacturing capacity, forcing rapid investment in specialised capabilities. Geopolitical tensions are disrupting supply chains, making regional diversification and de-risking strategies more critical than ever. Meanwhile, raw material shortages, rising costs, and labour constraints are challenging production efficiency, pushing CDMOs toward automation and digitalisation. At the same time, pharma companies are no longer just looking for vendors; they need long-term strategic partners who can offer flexibility, scalability, and innovation.